A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy

REFERENCES

• Maynard JE. Hepatitis B: global importance and need for control. Vaccine. 1990;8 Suppl:S18-20 (discussion S1–3).
   Google Scholar
• Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486–500.
   PubMed Web of Science ®Google Scholar
• Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13–23.
   PubMed Web of Science ®Google Scholar
• Tanaka J, Kumagai J, Katayama K, Komiya Y, Mizui M, Yamanaka R, et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirol-ogy. 2004;47:32–40.
   PubMed Web of Science ®Google Scholar
• Hui CK, Bowden S, Jackson K, Au WY, Fong DY, Lie AK, et al. Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood. 2005;105:2616–7.
   PubMed Web of Science ®Google Scholar
• Umemura T, Kiyosawa K. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med. 2006;45:747–8.
   PubMed Web of Science ®Google Scholar
• Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47:e52–6.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: rec-ommendations of an international task force. Ann Rheum Dis. 2010;69:631–7.
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guide-lines for screening, treatment, and management of lupus nephri-tis. Arthritis Care Res (Hoboken). 2012;64:797–808.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310–7.
   PubMed Web of Science ®Google Scholar
• Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010;62: 749–54.
   PubMed Web of Science ®Google Scholar
• Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, Lopez-Roses L, Brito-Zeron P, Perez-de-Lis M, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Balti-more). 2011;90:359–71.
   PubMed Web of Science ®Google Scholar
• Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al. Prevalence of reactivation of hepatitis B virus replica-tion in rheumatoid arthritis patients. Mod Rheumatol. 2011;21: 16–23.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Calabrese LH. Let the fog be lifted: screening for hepatitis B virus before biological therapy. Ann Rheum Dis. 2011;70:1701–3.
   PubMed Web of Science ®Google Scholar
• Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, et al. Kinetics of viral loads and risk of hepatitis B virus reacti-vation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011;70:1719–25.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Urata Y. Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-alpha inhibitors. Hepatol Res. 2012;42:333–9.
   PubMed Web of Science ®Google Scholar
• Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum. 2001;44: 339–42.
   PubMed Web of Science ®Google Scholar
• Gwak GY, Koh KC, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface anti-gen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol. 2007;25:888–9.
   Google Scholar
• Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheu-matic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65:983–9.
   Google Scholar
• Tsubouchi H, Kumada H, Kiyosawa K, Mochida S, Sakaida I, Tanaka E, et al. Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infec-tion-joint report of the Intractable Liver Disease Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy For Viral Hepatitis. Acta Hepatol Jpn. 2009;50:38–42.
   Google Scholar
• Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive ther-apy or chemotherapy. Hepatol Res. 2012;42:627–36.
   PubMed Web of Science ®Google Scholar
• Mochida S, Takikawa Y, Nakayama N, Oketani M, Naiki T, Yamagishi Y, et al. Diagnostic criteria of acute liver failure: a report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res. 2011;41:805–12.
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Mochida S, Matsui A, Nakayama N, Nagoshi S, Toda G. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res. 2008;38:646–57.
   PubMed Web of Science ®Google Scholar
• Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol. 2012;47:849–61.
   Google Scholar
• Oketani M, Ido A, Nakayama N, Takikawa Y, Naiki T, Yamagishi Y, et al. Etiology and prognosis of fulminant hepatitis and late onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 2012 (in press).
   Google Scholar
• The Intractable Hepato-Biliary Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis in the Health and Labour Sciences Research. Guideline for prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infec-tion. 2009. http://www.jsh.or.jp/medical/documents/20120329.pdf. Last updated on Sept 26,2011; cited Sept 12,2012.
   Google Scholar
• Mimura T, Yamamoto K, Nojima Y, Hiromura K, Miyasaka N, Shiozawa S, et al. HBV reactivation in the immunosuppressed patients with rheumatic diseases (Abstract). Mod Rheumatol suppl. 2011;21:5163–4.
   Google Scholar
• Mochida S, Kusumoto S, Ido A, Ikeda K, Bessho M, Dan K, et al. Prospective study to clarify the current status of HBV reactivation in patients receiving immunosuppressive and anticancer drugs (2011). In: Annual Report by The Health and Labour Sciences Research Group for "Clarification of current status for reactiva-tion of hepatitis B virus associated with immunosuppressants and antineoplatics and establishment of the preventive measures". 2012. p. 1–32 (in Japanese).
   Google Scholar
• Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006;44:1656–65.
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 2007;51:902–11.
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503–14.
   PubMed Web of Science ®Google Scholar
• Ide T, Sata M, Chayama K, Shindo M, Toyota J, Mochida S, et al. Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy. Hepatol Int. 2010;4:594–600.
   PubMed Web of Science ®Google Scholar
• Shindo M, Chayama K, Mochida S, Toyota J, Tomita E, Kumada H, et al. Antiviral activity, dose—response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial. Hepatol Int. 2009;3:445–52.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepa-tol. 2009;50:227–42.
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Tanaka E, Suzuki Y, Kobayashi M, Tanaka Y, Shinkai N, et al. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nude-osfffide analogs in patients with chronic hepatitis B. Hepatol Res. 2012;42:139–49.
   PubMed Web of Science ®Google Scholar
• Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.
   PubMed Web of Science ®Google Scholar